News

New biomarker for Alzheimer onset
Enlarge image

ResearchBelgiumFinlandUK

New biomarker for Alzheimer onset

27.06.2012 - GE Healthcare and the VTT Technical Research Centre have joint forces on validating a biomarker signature in a large patient cohort.

Espoo/Chalfont St Giles/Beerse – Last December, researchers from the VTT discovered a serum biochemical signature which predicts progression to Alzheimer’s disease (AD) months or even years before the first symptoms of the disease occur (Transl. Psychiatry 1, e57). Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues. The first research projects have already begun, said VTT’s research professor Matej Orešič to EuroBiotechNews.eu. "We use a key biomarker metabolite (2,4-dihydroxybutanoic acid) that is a known cerebrospinal fluid (CSF) metabolite. We have preliminary data linking this metabolite measured in CSF to AD", says Orešič.

In 2010 GE Healthcare entered into a “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programmes and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has, over the past years, built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”

http://www.european-biotechnology-news.com/news/news/2012-02/new-biomarker-for-alzheimer-onset.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products